HRP20191179T1 - Spojevi amida kao agonisti 5-ht4 receptora - Google Patents

Spojevi amida kao agonisti 5-ht4 receptora Download PDF

Info

Publication number
HRP20191179T1
HRP20191179T1 HRP20191179TT HRP20191179T HRP20191179T1 HR P20191179 T1 HRP20191179 T1 HR P20191179T1 HR P20191179T T HRP20191179T T HR P20191179TT HR P20191179 T HRP20191179 T HR P20191179T HR P20191179 T1 HRP20191179 T1 HR P20191179T1
Authority
HR
Croatia
Prior art keywords
methyl
amino
carboxamide
chloro
azabicyclo
Prior art date
Application number
HRP20191179TT
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Abdul Rasheed Mohammed
Sangram Keshari SARAF
Narsimha BOGARAJU
Ramkumar Subramanian
Pradeep Jayarajan
Gopinadh Bhyrapuneni
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Limited filed Critical Suven Life Sciences Limited
Publication of HRP20191179T1 publication Critical patent/HRP20191179T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Claims (7)

1. Spoj opće formule (I), ili stereoizomer, farmaceutski prihvatljiva sol tog spoja, u kojem, je ili X je halogen ili vodik; je
ili " " je točka vezivanja; "--------" označava vezu ili da nema veze; R1 je vodik, fluor ili hidroksil; R2 je vodik ili fluor; uz uvjet da je R2 jednako fluro kada "--------" nije veza; i "n" je 1 ili 2.
2. Spoj prema patentnom zahtjevu 1, naznačen time što: je ili X je klor, brom ili vodik; je
ili " " je točka vezivanja; i R1 je vodik.
3. Spoj prema patentnom zahtjevu 1, naznačen time što je spoj izabran od, (a) spojeva formule (Ib-1): ili stereoizomera, farmaceutski prihvatljive soli tog spoja, u kojem, je ili " " je točka vezivanja; X je klor; (b) spojevi formule (Ib-2): ili stereoizomera, farmaceutski prihvatljive soli tog spoja, u kojem, je X je klor; " " je točka vezivanja; (c) spojevi formule (Id-1): ili stereoizomera, farmaceutski prihvatljive soli tog spoja, u kojem, "--------" predstavlja vezu ili da nema veze; je ili X je klor ili brom; " " je točka vezivanja; R2 je vodik ili fluor; uz uvjet da je R2 fluor kada "--------" nije veza; (d) spojevi formule (Id-2): ili stereoizomera, farmaceutski prihvatljive soli tog spoja, u kojem, "--------" predstavlja vezu ili da nema veze; je X je klor; " " je točka vezivanja; R2 je vodik ili fluor; uz uvjet da je R2 fluor kada "--------" nije veza; (e) spojevi formule (Ie-1): ili stereoizomera, farmaceutski prihvatljive soli tog spoja, u kojem, je ili X je klor; " " je točka vezivanja; (f) spojevi formule (Ie-2): ili stereoizomera, farmaceutski prihvatljive soli tog spoja, "--------" predstavlja vezu ili da nema veze; je X je klor; " " je točka vezivanja; i (g) spojevi formule (If-1): ili stereoizomera, farmaceutski prihvatljive soli tog spoja, u kojem, je ili X je klor ili brom; R2 je vodik ili fluor; "n" je 1 ili 2.
4. Spoj prema patentnom zahtjevu 1, koji je izabran iz grupe koja se sastoji od sljedećih: 5-Amino-6-kloro-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid hidroklorid; 5-Amino-6-kloro-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid hemifumarat; 5-Amino-6-kloro-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-6-kloro-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[3-(tetrahidro-2H-piran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[3-(tetrahidro-2H-piran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid; (R,S) 5-Amino-6-kloro-N-{[3-(tetrahidro-3-furanilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid; (R,S) 5-Amino-6-kloro-N-{[3-(tetrahidro-3-furanilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-6-bromo-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid; 5-Amino-6-bromo-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid L(+)-tartarat; 4-Amino-5-kloro-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid hidroklorid; 4-Amino-5-kloro-N-{[3-(tetrahidro-2H-piran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(tetrahidro-2H-piran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid oksalat; 4-Amino-5-kloro-N-{[3-(1-metoksikarbonilpiperidin-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(1-metoksikarbonilpiperidin-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid oksalat; 4-Amino-5-kloro-2-metil-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-2-metil-N-{[3-(tetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid hidroklorid; 4-Amino-5-kloro-N-[(3-izopropil-3-azabiciklo[3.1.0]heks-6-il)metil]-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-kloro-N-[(3-izopropil-3-azabiciklo[3.1.0]heks-6-il)metil]-2,3-dihidrobenzofuran-7-karboksamid oksalat; 4-Amino-5-kloro-N-{[3-(ciklobutilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzo furan-7-karboksamid; 4-Amino-5-kloro-N-{[3-(ciklobutilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid oksalat; 4-Amino-5-kloro-N-{[3-(1-metoksikarbonilpiperidin-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(1-metoksikarbonilpiperidin-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid L(+)-tartarat; 4-Amino-5-kloro-N-{[3-(tetrahidropiran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(tetrahidropiran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid L(+)-tartarat; 4-Amino-5-kloro-N-{[3-(tetrahidropiran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(tetrahidropiran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid oksalat; 4-Amino-5-bromo-N-{[3-(tetrahidropiran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-bromo-N-{[3-(tetrahidropiran-4-il)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid oksalat; 5-Amino-6-kloro-N-{[3-(4-hidroksitetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[3-(4-hidroksitetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid L(+)-tartarat; 4-Amino-5-kloro-N-{[3-(4-hidroksitetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(4-hidroksitetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid oksalat; 4-Amino-5-kloro-N-{[3-(4-hidroksitetrahidropiran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(4-hidroksitetrahidropiran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid oksalat; 5-Amino-6-kloro-N-{[3-(4-fluorotetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[3-(4-fluorotetrahidro-2H-piran-4-ilmetil)-3-azabiciklo[3.1.0]heks-6-il]metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-6-kloro-N-{[3-(2-hidroksi-2-metilpropil)-3-azabiciklo[3.1.0]heks-6-il] metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[3-(2-hidroksi-2-metilpropil)-3-azabiciklo[3.1.0]heks-6-il] metil}kroman-8-karboksamid L(+)-tartarat; 4-Amino-5-kloro-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}benzofuran-7-karboksamid hidroklorid; 4-Amino-5-kloro-N-{[3-(2-hidroksi-2-metilpropil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(2-hidroksi-2-metilpropil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid oksalat; 5-Amino-6-kloro-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-6-bromo-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}kroman-8-karboksamid; 5-Amino-6-bromo-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}kroman-8-karboksamid L(+)-tartarat; 4-Amino-5-kloro-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}benzofuran-7-karboksamid L(+)-tartarat; 4-Amino-5-kloro-N-{[3-(2-hidroksi-2-metilpropil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(2-hidroksi-2-metilpropil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid L(+)-tartarat; 4-Amino-5-kloro-2-metil-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-2-metil-N-{[4-fluoro-1-(2-hidroksi-2-metilpropil)-4-piperidinil]metil}benzofuran-7-karboksamid L(+)-tartarat; 4-Amino-5-kloro-2-metil-N-{[3-(2-hidroksi-2-metilpropil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 5-Amino-6-kloro-N-{[1-(2-fluoro-2-metilpropil)-4-fluoro-4-piperidinil]metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[1-(2-fluoro-2-metilpropil)-4-fluoro-4-piperidinil]metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-6-kloro-N-{[3-(3-hidroksi-2,2-dimetilpropil)-3-azabiciklo[3.1.0]heks-6-il] metil}kroman-8-karboksamid; 5-Amino-6-kloro-N-{[3-(3-hidroksi-2,2-dimetilpropil)-3-azabiciklo[3.1.0]heks-6-il] metil}kroman-8-karboksamid L(+)-tartarat; 5-Amino-6-kloro-N-{[3-(3-metoksi-2,2-dimetilpropil)-3-azabiciklo[3.1.0]heks-6-il] metil}kroman-8-karboksamid; 4-Amino-5-kloro-N-{[3-(3-metoksipropil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(3-metoksipropil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid oksalat; 4-Amino-5-kloro-N-{[3-(3-metoksipropil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-N-{[3-(3-metoksipropil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid hidroklorid; 4-Amino-5-kloro-2-metil-N-{[3-(3-metoksipropil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid; 4-Amino-5-kloro-2-metil-N-{[3-(3-metoksipropil)-3-azabiciklo[3.1.0]heks-6-il]metil}benzofuran-7-karboksamid hidroklorid; i 4-Amino-5-bromo-N-{[3-(3-metoksipropil)-3-azabiciklo[3.1.0]heks-6-il]metil}-2,3-dihidrobenzofuran-7-karboksamid oksalat.
5. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 4 i farmaceutski prihvatljive ekscipijense ili nosače.
6. Farmaceutska kompozicija prema patentnom zahtjevu 5, za uporabu u liječenju kliničkih stanja posredovanih preko 5-HT4 receptora izabranih od Alzheimerove bolesti, shizofrenije, poremećaja deficita pažnje i hiperaktivnosti, Huntingtonove bolesti, Parkinsonove bolesti, depresije ili psihijatrijskih poremećaja.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, za uporabu u liječenju Alzheimerove bolesti, shizofrenije, poremećaja deficita pažnje i hiperaktivnosti, Huntingtonove bolesti, Parkinsonove bolesti, depresije ili psihijatrijskih poremećaja.
HRP20191179TT 2015-02-13 2019-07-01 Spojevi amida kao agonisti 5-ht4 receptora HRP20191179T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN709CH2015 2015-02-13
PCT/IN2016/000008 WO2016128990A1 (en) 2015-02-13 2016-01-07 Amide compounds as 5-ht4 receptor agonists
EP16711355.4A EP3265459B1 (en) 2015-02-13 2016-01-07 Amide compounds as 5-ht4 receptor agonists

Publications (1)

Publication Number Publication Date
HRP20191179T1 true HRP20191179T1 (hr) 2019-10-04

Family

ID=55588327

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191179TT HRP20191179T1 (hr) 2015-02-13 2019-07-01 Spojevi amida kao agonisti 5-ht4 receptora

Country Status (29)

Country Link
US (1) US9957257B2 (hr)
EP (1) EP3265459B1 (hr)
JP (1) JP6487564B2 (hr)
KR (1) KR101966576B1 (hr)
CN (1) CN107406434B (hr)
AU (1) AU2016217461B2 (hr)
BR (1) BR112017017275A2 (hr)
CA (1) CA2975973C (hr)
CY (1) CY1121898T1 (hr)
DK (1) DK3265459T3 (hr)
EA (1) EA034618B1 (hr)
ES (1) ES2734734T3 (hr)
HR (1) HRP20191179T1 (hr)
HU (1) HUE045667T2 (hr)
IL (1) IL253848B (hr)
LT (1) LT3265459T (hr)
MA (1) MA41633B1 (hr)
MD (1) MD3265459T2 (hr)
ME (1) ME03430B (hr)
MX (1) MX368214B (hr)
NZ (1) NZ734400A (hr)
PL (1) PL3265459T3 (hr)
PT (1) PT3265459T (hr)
RS (1) RS59066B1 (hr)
SG (1) SG11201706501VA (hr)
SI (1) SI3265459T1 (hr)
TR (1) TR201909997T4 (hr)
WO (1) WO2016128990A1 (hr)
ZA (1) ZA201705292B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619829T3 (es) 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
CN110818661B (zh) * 2019-12-02 2021-08-06 上海再启生物技术有限公司 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
CA2598516C (en) 2005-02-25 2010-05-11 Pfizer Inc. Benzisoxazole derivatives
ES2333545T3 (es) 2005-07-22 2010-02-23 Pfizer, Inc. Derivados de indazolcarboxamida como agonistas de receptores 5ht4.
PE20070713A1 (es) * 2005-10-28 2007-09-27 Glaxo Group Ltd 4-amino-5-cloro-n-{[1-(tetrahidro-2h-piran-4-ilmetil)-4-piperidinil]metil}-1-benzofuran-7-carboxamida en el tratamiento de alzheimer
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
MX343165B (es) * 2010-02-12 2016-10-26 Raqualia Pharma Inc Agonistas del receptor 5-ht4 para el tratamiento de demencia.
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
PL2758394T3 (pl) * 2011-09-19 2015-08-31 Suven Life Sciences Ltd Związki heteroarylowe jako ligandy receptora 5-HT4
ES2674993T3 (es) * 2013-03-20 2018-07-05 Suven Life Sciences Limited Derivados de 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-HT4
SG11201604849YA (en) * 2013-12-16 2016-07-28 Suven Life Sciences Ltd INDAZOLE COMPOUNDS AS 5-HT<sb>4</sb> RECEPTOR AGONISTS

Also Published As

Publication number Publication date
DK3265459T3 (da) 2019-07-15
EA201791829A1 (ru) 2018-05-31
ZA201705292B (en) 2019-06-26
SI3265459T1 (sl) 2019-09-30
CN107406434B (zh) 2020-09-11
AU2016217461A1 (en) 2017-09-14
MD3265459T2 (ro) 2019-09-30
AU2016217461B2 (en) 2018-07-05
KR20170117167A (ko) 2017-10-20
JP2018509396A (ja) 2018-04-05
MA41633B1 (fr) 2019-07-31
RS59066B1 (sr) 2019-09-30
CY1121898T1 (el) 2020-10-14
ES2734734T3 (es) 2019-12-11
ME03430B (me) 2020-01-20
PL3265459T3 (pl) 2019-09-30
PT3265459T (pt) 2019-07-17
MX2017010348A (es) 2018-06-07
IL253848B (en) 2018-01-31
CA2975973A1 (en) 2016-08-18
TR201909997T4 (tr) 2019-07-22
EP3265459A1 (en) 2018-01-10
EA034618B1 (ru) 2020-02-27
WO2016128990A1 (en) 2016-08-18
EP3265459B1 (en) 2019-05-15
US20180051011A1 (en) 2018-02-22
IL253848A0 (en) 2017-09-28
SG11201706501VA (en) 2017-09-28
MX368214B (es) 2019-09-24
LT3265459T (lt) 2019-08-26
HUE045667T2 (hu) 2020-01-28
JP6487564B2 (ja) 2019-03-20
MA41633A (fr) 2019-05-15
BR112017017275A2 (pt) 2018-04-17
CA2975973C (en) 2019-07-16
NZ734400A (en) 2018-03-23
CN107406434A (zh) 2017-11-28
KR101966576B1 (ko) 2019-04-05
US9957257B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
HRP20191179T1 (hr) Spojevi amida kao agonisti 5-ht4 receptora
PH12016501440A1 (en) Novel heterocyclic compounds
CY1121601T1 (el) Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
BRPI0607532A2 (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
EA201991123A1 (ru) ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA201591204A3 (ru) Новые хиральные n-ацил-5,6,7,(8-замещенные)-тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез
EA201692465A1 (ru) Кристаллические соли (s)-6-((1-ацетилпиперидин-4-ил)амино)-n-(3-(3,4-дигидроизохинолин-2(1h)-ил)-2-гидроксипропил)пиримидин-4-карбоксамида
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EA201891143A1 (ru) Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
BR112017012396A2 (pt) combinação farmacêutica que compreende um agonista seletivo do receptor s1p1
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
EA201170256A1 (ru) Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина
BR112012028992B8 (pt) 1 - [(4-hidroxipiredina-4-il)metil]piridina-2 (1h) -ona, método de preparação e utilização dos mesmos
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
MX2015013059A (es) Sales, co-cristales, y polimorfos de un compuesto ansiolitico.
BR112021018372A2 (pt) Composto acilaminopirrolo-piridona, método para preparar o referido composto, composição farmacêutica e uso do mesmo
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
PH12017501736A1 (en) Indole derivatives